Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort.

Mihai C, Distler O, Gheorghiu AM, Constantin PI, Dobrota R, Jordan S, Smith V, Hachulla E, Henes J, Siegert E, Vettori S, Müller-Ladner U, Matucci Cerinic M, Allanore Y; EUSTAR .

Rheumatology (Oxford). 2019 Dec 2. pii: kez558. doi: 10.1093/rheumatology/kez558. [Epub ahead of print]

PMID:
31790136
2.

Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study.

Jaeger VK, Tikly M, Xu D, Siegert E, Hachulla E, Airò P, Valentini G, Matucci Cerinic M, Distler O, Cozzi F, Carreira P, Allanore Y, Müller-Ladner U, Ananieva LP, Balbir-Gurman A, Distler JHW, Czirják L, Li M, Henes J, Jimenez SA, Smith V, Damjanov N, Denton CP, DelGaldo F, Saketkoo LA, Walker UA; EUSTAR co-authors .

Rheumatology (Oxford). 2019 Nov 4. pii: kez486. doi: 10.1093/rheumatology/kez486. [Epub ahead of print]

PMID:
31680161
3.

Clinical and Echocardiographic Associates of All-Cause Mortality and Cardiovascular Outcomes in Patients With Systemic Sclerosis.

van Wijngaarden SE, Boonstra M, Bloem B, Cassani D, Tanner FC, Jordan S, Distler O, Delgado V, Bax JJ, de Vries-Bouwstra JK, Ajmone Marsan N.

JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 1):2273-2276. doi: 10.1016/j.jcmg.2019.05.017. Epub 2019 Jul 17. No abstract available.

PMID:
31326475
4.

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis.

Sobanski V, Giovannelli J, Allanore Y, Riemekasten G, Airò P, Vettori S, Cozzi F, Distler O, Matucci-Cerinic M, Denton C, Launay D, Hachulla E; EUSTAR Collaborators.

Arthritis Rheumatol. 2019 Sep;71(9):1553-1570. doi: 10.1002/art.40906. Epub 2019 Aug 12.

5.

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.

Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network.

Ann Rheum Dis. 2019 Jul;78(7):979-987. doi: 10.1136/annrheumdis-2018-214816. Epub 2019 Apr 9.

PMID:
30967395
6.

Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: a cross-sectional study.

Osthoff M, Jaeger VK, Heijnen IAFM, Trendelenburg M, Jordan S, Distler O, Walker UA.

Arthritis Res Ther. 2019 Mar 18;21(1):76. doi: 10.1186/s13075-019-1859-1.

7.

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.

Wu W, Jordan S, Graf N, de Oliveira Pena J, Curram J, Allanore Y, Matucci-Cerinic M, Pope JE, Denton CP, Khanna D, Distler O; EUSTAR Collaborators.

Ann Rheum Dis. 2019 May;78(5):648-656. doi: 10.1136/annrheumdis-2018-213455. Epub 2019 Mar 9.

8.

Increased expression of the TNF superfamily member LIGHT/TNFSF14 and its receptors (HVEM and LTßR) in patients with systemic sclerosis.

Gindzienska-Sieskiewicz E, Distler O, Reszec J, Jordan S, Bielecki P, Sieskiewicz A, Sulik A, Lukasik M, Bielecki M, Kowal K, Kowal-Bielecka O.

Rheumatology (Oxford). 2019 Mar 1;58(3):502-510. doi: 10.1093/rheumatology/key348.

PMID:
30508197
9.

Response to: 'Will SPAR be useful in the usual patients with scleroderma?' by Chattopadhyay et al.

Wu W, Jordan S, Distler O.

Ann Rheum Dis. 2019 Nov;78(11):e126. doi: 10.1136/annrheumdis-2018-214270. Epub 2018 Nov 10. No abstract available.

10.

Abnormal esophageal motility during a solid test meal in systemic sclerosis-detection even in very early disease and association with disease progression.

Bütikofer S, Jordan S, Sauter M, Hollenstein M, Heinrich H, Freitas-Queiroz N, Kuntzen T, Ang D, Oberacher M, Maurer B, Schwizer W, Fox M, Distler O, Misselwitz B.

Neurogastroenterol Motil. 2019 Jan;31(1):e13480. doi: 10.1111/nmo.13480. Epub 2018 Oct 1.

PMID:
30276930
11.

European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis.

Abignano G, Blagojevic J, Bissell LA, Dumitru RB, Eng S, Allanore Y, Avouac J, Bosello S, Denton CP, Distler O, Ferraccioli G, Jordan S, Matucci-Cerinic M, Ong V, Messenger M, Hutchinson M, Buch MH, Emery P, Del Galdo F.

Rheumatology (Oxford). 2019 Feb 1;58(2):254-259. doi: 10.1093/rheumatology/key271.

12.

Response to: 'Can we further SPARkle the SPAR model?' by Kavadichanda et al.

Wu W, Jordan S, Distler O.

Ann Rheum Dis. 2019 Sep;78(9):e94. doi: 10.1136/annrheumdis-2018-213962. Epub 2018 Jul 21. No abstract available.

PMID:
30032115
13.

Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.

Wu W, Jordan S, Becker MO, Dobrota R, Maurer B, Fretheim H, Ye S, Siegert E, Allanore Y, Hoffmann-Vold AM, Distler O.

Ann Rheum Dis. 2018 Sep;77(9):1326-1332. doi: 10.1136/annrheumdis-2018-213201. Epub 2018 Jun 6.

PMID:
29875097
14.

Nodular Regenerative Hyperplasia of the Liver: A Rare Vascular Complication in Systemic Sclerosis.

Graf L, Dobrota R, Jordan S, Wildi LM, Distler O, Maurer B.

J Rheumatol. 2018 Jan;45(1):103-106. doi: 10.3899/jrheum.170292. Epub 2017 Nov 1.

PMID:
29093156
15.

Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis.

Stamm A, Saxer S, Lichtblau M, Hasler ED, Jordan S, Huber LC, Bloch KE, Distler O, Ulrich S.

Eur Respir J. 2016 Dec;48(6):1658-1667. doi: 10.1183/13993003.00990-2016. Epub 2016 Oct 6.

16.

Effects of rituximab in connective tissue disorders related interstitial lung disease.

Lepri G, Avouac J, Airò P, Anguita Santos F, Bellando-Randone S, Blagojevic J, Garcia Hernàndez F, Gonzalez Nieto JA, Guiducci S, Jordan S, Limaye V, Maurer B, Selva-O'Callaghan A, Riccieri V, Distler O, Matucci-Cerinic M, Allanore Y.

Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):181-185. Epub 2016 Oct 14.

17.

The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index.

Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P, Czirják L, Denton CP, Distler O, Hachulla E, Herrick AL, Kowal-Bielecka O, Pope J, Müller-Ladner U, Riemekasten G, Avouac J, Frerix M, Jordan S, Minier T, Siegert E, Ong VH, Vettori S, Allanore Y.

Ann Rheum Dis. 2017 Jan;76(1):270-276. doi: 10.1136/annrheumdis-2016-209768. Epub 2016 Sep 12.

PMID:
27621285
18.

Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.

Dobrota R, Maurer B, Graf N, Jordan S, Mihai C, Kowal-Bielecka O, Allanore Y, Distler O; EUSTAR coauthors.

Ann Rheum Dis. 2016 Oct;75(10):1743-8. doi: 10.1136/annrheumdis-2015-208024. Epub 2016 Mar 25.

19.

Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.

Suliman YA, Dobrota R, Huscher D, Nguyen-Kim TD, Maurer B, Jordan S, Speich R, Frauenfelder T, Distler O.

Arthritis Rheumatol. 2015 Dec;67(12):3256-61. doi: 10.1002/art.39405.

20.

Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice.

Jordan S, Maurer B, Toniolo M, Michel B, Distler O.

Rheumatology (Oxford). 2015 Aug;54(8):1454-8. doi: 10.1093/rheumatology/keu530. Epub 2015 Mar 11.

Supplemental Content

Loading ...
Support Center